Matches in SemOpenAlex for { <https://semopenalex.org/work/W2330509954> ?p ?o ?g. }
Showing items 1 to 76 of
76
with 100 items per page.
- W2330509954 endingPage "452" @default.
- W2330509954 startingPage "445" @default.
- W2330509954 abstract "On October 19, 2010, the Food and Drug Administration approved dabigatran (Pradaxa) for reducing the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation (AF). The use of warfarin sodium has been considered a mainstay therapy for the prevention of thromboembolic complications secondary to AF. Despite its efficacy among oral antithrombotic agents for the prevention of thromboembolic complications secondary to AF, only about 67% of candidates for warfarin receive appropriate antithrombotic therapy. Dosed twice daily, dabigatran offers recipients the ability to forego regular international normalized ratio coagulation monitoring as well as eliminating dietary restrictions (i.e., vitamin K) associated with warfarin therapy. In a 2011 guideline update, dabigatran has been recognized by the American College of Cardiology and the American Heart Association as a useful alternative to warfarin in patients with AF who are at risk for thromboembolic complications and who are without severe renal or hepatic impairment. The Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) study is the only direct, prospective, comparative clinical trial of dabigatran versus warfarin to date that enrolled subjects for the purpose of examining the ability of dabigatran to prevent stroke and thromboembolic complications associated with nonvalvular AF. Currently, the published literature has not adequately defined which patient populations would be most suitable to treat with dabigatran. While dabigatran has a place in the therapeutic prevention stroke and systemic embolism associated with AF, careful consideration of the risks and benefits of therapy is recommended." @default.
- W2330509954 created "2016-06-24" @default.
- W2330509954 creator A5052051246 @default.
- W2330509954 creator A5057108353 @default.
- W2330509954 date "2012-06-01" @default.
- W2330509954 modified "2023-10-18" @default.
- W2330509954 title "Dabigatran for the Prevention of Thromboembolic Complications in the Elderly: A RE-LY-able Alternative to Warfarin?" @default.
- W2330509954 cites W1981294902 @default.
- W2330509954 cites W1982179895 @default.
- W2330509954 cites W1986637035 @default.
- W2330509954 cites W1993614294 @default.
- W2330509954 cites W2006632121 @default.
- W2330509954 cites W2020404695 @default.
- W2330509954 cites W2051910688 @default.
- W2330509954 cites W2057250169 @default.
- W2330509954 cites W2060630424 @default.
- W2330509954 cites W2064357176 @default.
- W2330509954 cites W2095647706 @default.
- W2330509954 cites W2136489990 @default.
- W2330509954 cites W2141889414 @default.
- W2330509954 cites W2157459435 @default.
- W2330509954 cites W2164615468 @default.
- W2330509954 cites W2164861810 @default.
- W2330509954 cites W2172245650 @default.
- W2330509954 doi "https://doi.org/10.4140/tcp.n.2012.445" @default.
- W2330509954 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22698551" @default.
- W2330509954 hasPublicationYear "2012" @default.
- W2330509954 type Work @default.
- W2330509954 sameAs 2330509954 @default.
- W2330509954 citedByCount "1" @default.
- W2330509954 countsByYear W23305099542012 @default.
- W2330509954 crossrefType "journal-article" @default.
- W2330509954 hasAuthorship W2330509954A5052051246 @default.
- W2330509954 hasAuthorship W2330509954A5057108353 @default.
- W2330509954 hasConcept C126322002 @default.
- W2330509954 hasConcept C127413603 @default.
- W2330509954 hasConcept C177713679 @default.
- W2330509954 hasConcept C2776301958 @default.
- W2330509954 hasConcept C2777015399 @default.
- W2330509954 hasConcept C2778810321 @default.
- W2330509954 hasConcept C2779161974 @default.
- W2330509954 hasConcept C2780645631 @default.
- W2330509954 hasConcept C71924100 @default.
- W2330509954 hasConcept C78519656 @default.
- W2330509954 hasConceptScore W2330509954C126322002 @default.
- W2330509954 hasConceptScore W2330509954C127413603 @default.
- W2330509954 hasConceptScore W2330509954C177713679 @default.
- W2330509954 hasConceptScore W2330509954C2776301958 @default.
- W2330509954 hasConceptScore W2330509954C2777015399 @default.
- W2330509954 hasConceptScore W2330509954C2778810321 @default.
- W2330509954 hasConceptScore W2330509954C2779161974 @default.
- W2330509954 hasConceptScore W2330509954C2780645631 @default.
- W2330509954 hasConceptScore W2330509954C71924100 @default.
- W2330509954 hasConceptScore W2330509954C78519656 @default.
- W2330509954 hasIssue "6" @default.
- W2330509954 hasLocation W23305099541 @default.
- W2330509954 hasLocation W23305099542 @default.
- W2330509954 hasOpenAccess W2330509954 @default.
- W2330509954 hasPrimaryLocation W23305099541 @default.
- W2330509954 hasRelatedWork W1993190469 @default.
- W2330509954 hasRelatedWork W2018572947 @default.
- W2330509954 hasRelatedWork W2022043463 @default.
- W2330509954 hasRelatedWork W2037180721 @default.
- W2330509954 hasRelatedWork W2039688335 @default.
- W2330509954 hasRelatedWork W2090821460 @default.
- W2330509954 hasRelatedWork W2104343448 @default.
- W2330509954 hasRelatedWork W2134968660 @default.
- W2330509954 hasRelatedWork W2418235060 @default.
- W2330509954 hasRelatedWork W2896204226 @default.
- W2330509954 hasVolume "27" @default.
- W2330509954 isParatext "false" @default.
- W2330509954 isRetracted "false" @default.
- W2330509954 magId "2330509954" @default.
- W2330509954 workType "article" @default.